Nurix Therapeutics, Inc.
NRIX
$13.59
$0.403.03%
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -39.55% | -32.38% | -83.49% | -1.93% | 10.19% |
| Total Depreciation and Amortization | 27.41% | 22.52% | 22.74% | 22.26% | 28.31% |
| Total Amortization of Deferred Charges | -7.14% | -- | -- | -- | 16.67% |
| Total Other Non-Cash Items | -16.84% | -26.41% | -13.98% | -23.67% | -20.65% |
| Change in Net Operating Assets | -99.24% | 81.73% | -12.04% | 45.14% | 3,160.35% |
| Cash from Operations | -282.66% | -2.54% | -114.98% | 13.42% | 170.32% |
| Capital Expenditure | 18.57% | 4.55% | -79.35% | -26.66% | -0.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,076.72% | -175.26% | -387.53% | 109.30% | -120.47% |
| Cash from Investing | -879.73% | -193.69% | -399.03% | 121.02% | -126.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,864,485.71% | 2,586.03% | 950,968.00% | 9.66% | -85.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,864,485.71% | 2,586.03% | 950,908.00% | 9.66% | 105.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.12% | -6.56% | 163.82% | 84.42% | -27.16% |
